Journal Home
Search for

Volume 36, Issue 8, Pages 725-730 (August 2010)


View previous. 4 of 16 View next.

Results of single-probe microwave ablation of metastatic liver cancer

R. Hompesc, S. Fieuwsad, R. Aertsc, M. Thijsb, F. Penninckxc, B. TopalcCorresponding Author Informationemail address

Accepted 10 May 2010.

Abstract 

Aims

Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA vs. radiofrequency ablation (RFA) of liver metastases smaller than 3cm in patients without underlying liver disease.

Methods

Sixteen liver metastases were treated using MWA, and matched for size and localisation with 13 metastases treated by RFA. Tumour diameters and postoperative ablation diameters were recorded (D1 transverse; D2 antero-posterior; D3 cranio-caudal; mm) on computed tomography scans.

Results

Median D1, D2, and D3 ablation diameters after MWA vs. RFA were 18.5 (12–64) vs. 34 (16–41)mm (p=0.003), 26 (14–60) vs. 35 (28–40)mm (p=0.046), and 20 (10–73) vs. 32 (20–45)mm (p=0.025), respectively. As compared to RFA, the variability between the lesions after MWA was significantly higher for D2 (p<0.0001) and D3 (p=0.002) but not for D1 (p=0.15). The ablation diameters were less uniform after MWA than after RFA (p<0.001).

Conclusion

Ablation diameters after single-probe MWA of metastatic liver tumours are highly variable and suboptimal. Improvements are needed before MWA can be implemented routinely.

a Department of Biostatistics, Katholieke Universiteit Leuven, Belgium

b Department of Radiology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium

c Department of Abdominal Surgery, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium

d Department of Biostatistics, Universiteit Hasselt, Belgium

Corresponding Author InformationCorresponding author. Department of Abdominal Surgery, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16 344265; fax: +32 16 344832.

 ClinicalTrials.gov identifier: NCT00922181.

PII: S0748-7983(10)00121-6

doi:10.1016/j.ejso.2010.05.013


View previous. 4 of 16 View next.